Ignite Creation Date:
2024-05-05 @ 5:05 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00381173
Status:
COMPLETED
Last Update Posted:
2013-05-14
First Post:
2006-09-26
Brief Title:
A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing
Sponsor:
Eisai Inc
Organization:
Eisai Inc
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Renal Cancer |
| Breast Cancer |
| Ovarian Cancer |
| Prostate Cancer |
| Colon Cancer |
Keywords:
| Name | View |
|---|---|
| Advanced stage malignancies-ovary breast colon prostate | View |
| MGI PHARMA | View |
| ZYC3-002 | View |
| ZYC300 | View |
| plasmid DNA | View |
| cyclophosphamide | View |
| Cytoxan | View |
| advanced breast cancer | View |
| advanced ovarian cancer | View |
| hormone refractory prostate cancer | View |
| advanced colon cancer | View |
| advanced renal cancer | View |
| advanced stage malignancies | View |
| immune therapy | View |
| gene therapy | View |
| biologic therapy | View |
| T-regulatory cells | View |
| cancer vaccine | View |
| vaccine | View |